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Background: Remote ischemic preconditioning (RIPC) is a procedure that generates a brief 
period of ischemia followed by reperfusion. The role of RIPC in protecting myocardial ischemia 
during hemodialysis is not yet established. The aim of the study was to evaluate RIPC myocardial 
protection as evaluated by ultrasensitive I troponin in hemodialysis outpatients.
Patients and methods: A double-blind randomized trial with two groups: intervention sub-
mitted to RIPC and control group without RIPC. Intervention group received RIPC in three 
consecutive hemodialysis sessions. Blood samples were taken before and after each session. 
Blood urea nitrogen for calculation of single-pool Kt/v and ultrasensitive I troponin were mea-
sured to evaluate dialysis adequacy and myocardial injury. 
Results: A total of 47 patients were randomized. About 60.8% were men and 54% were dia-
betic. The mean single-pool Kt/v was 1.51 in the intervention group and 1.49 in control. The 
ultrasensitive troponin I measured no significant change from the time of collection: before or 
after dialysis. 
Conclusion: The RIPC applied in three consecutive sessions did not demonstrate superiority 
to control, therefore another study tested RIPC in 12 consecutive sessions with a positive result 
in myocardial protection. In our study, more than half of the patients were diabetic. Diabetic 
patients have a trend to show a lower response to RIPC because of the greater presence of col-
lateral coronary circulation. In summary, in this model there was no interference of RIPC in 
ultrasensitive troponin I values, but troponin had a high negative predictive value for myocardial 
infarction in all tested models.
Keywords: hemodialysis, chronic kidney disease, cardiac troponin, remote ischemic precon-
ditioning, myocardial infarction
Introduction
Remote ischemic preconditioning (RIPC) is defined as brief transient episodes of 
ischemia followed by a prolonged sustained episode of ischemia and reperfusion in 
the heart. It was first described by Murry et al in 1986, when they showed that brief 
ischemic episodes in dogs by the experimental occlusion of the left coronary artery 
reduced infarct extension caused by the occlusion of the circumflex artery and subse-
quent reperfusion.1 It was observed that these induced ischemic periods followed by 
reperfusion promote cardioprotection in situations in which this prolonged ischemic 
event is expected, like in cardiac surgeries, transplants or even percutaneous coronary 
angioplasty.2
Kadkhodaee et al reported protective effects in the kidney by pre- and post- 
conditioning in ischemic situations and induced reperfusion.3 Besides all other risk 
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factors, patients on hemodialysis have a common complica-
tion from the procedure associated with myocardial ischemia. 
With the prolonged decrease of oxygen supply, a left ventricu-
lar dysfunction can be observed in the long run, resulting in 
cardiac insufficiency and an increase in mortality.4 
A recent study reveals that conventional hemodialysis, 
besides being associated with endothelial injury, oxidative 
stress and high inflammatory activity, can induce microcir-
culation injury with consequent critical ischemia and tissue 
damages during the procedure.4, 5
It is known that cardiac troponin I (cTnI) and cardiac 
troponin T (cTnT) levels are usually elevated and related to 
mortality in such cases. A recent meta-analysis concluded 
that the elevation of cTnI and cTnT represents a 2.64- and 
1.74-fold increase in mortality, respectively.6
The aim of this study was to analyze the RIPC effect in 
myocardial injury by means of the measurement of cTnI in 
patients with chronic kidney disease on hemodialysis. 
Patients and methods
Study design
This is a randomized clinical trial. Patients were divided 
into two groups: experiment and control. Randomization 
was performed according to the list generated by the website 
www.randomizatiom.com, which was accessed only by the 
nurse in charge of the dialysis. Researchers remained blinded 
as to which group each patient belonged to. Patients on 
medications for the treatment of pre-existing diseases were 
not washed out.
Hemodialysis sessions were set to 3:30 hours, with blood 
flow of 300 mL/min, dialysate flow of 500 mL/min, sodium 
concentration of 140 mEq/L and bicarbonate of 34 mEq/L. 
The ultrafiltration value was defined according to the indi-
vidual need of each patient. Written informed consent was 
obtained from each participant included in this study; this 
study and its protocol were conducted in accordance with the 
Declaration of Helsinki, and the study was approved by the 
Faculdade de Medicina do ABC Ethics Committee (CAAE 
number 45920015.5.0000.0082).
Study interventions
The ischemic preconditioning consisted of a 5-minute inter-
ruption of the brachial blood flow using a Tycos sphygmoma-
nometer (Welch Allyn, Skaneateles Falls, NY, USA) inflated 
to 200 mmHg or until the distal blood flow was interrupted; 
subsequent deflation followed with the same rest period, and 
the procedure was repeated twice, totaling 30 minutes of 
intervention. The contralateral arm was chosen, next to the 
functioning arteriovenous fistula, and in the absence of the 
fistula, the right arm was used. The intervention occurred in 
the beginning of the dialysis session. The intervention group 
underwent three consecutive sessions of RIPC, whereas 
control group underwent none.
Interesting outcomes
The primary outcome was the decrease in ultrasensitive cTnI 
level when intervention and control groups were compared. 
The secondary outcome was mortality by any cause at time 
points 30 and 90 days, hospitalization due to cardiovascular 
event defined as acute coronary syndrome, pulmonary throm-
boembolism or cerebrovascular accident.
Variables of interest
The analysis of biochemical markers was carried out using 
blood samples collected at 2 and 7 days prior to the alloca-
tion, in the beginning of the first hemodialysis session, after 
the initial allocation.
Plasma cTnI levels were measured by ELISA assay, and 
their cutoff values were defined according to the constructed 
calibration curve. Values above the 99th percentile were 
considered altered.
 For dialysis adequacy, the values of single-pool Kt/V and 
the urea reduction ratio (URR) were considered adequate if 
they were ≥1.2 and 65%, respectively.
The analysis of the inflammatory markers was performed 
using the ELISA method. Cutoff values were set on a method-
by-method basis according to each used kit, following each 
manufacturer’s instructions.
Statistical analysis
This was a 40-patient pilot study. The sample was divided 
into two groups: 20 in the control group and 20 in the inter-
vention group.
Qualitative variables were presented with absolute and 
relative frequencies and analyzed by the chi-square test. 
Shapiro– Wilk test was used to verify the normality of quan-
titative variables. As the distribution was not normal, median 
values, along with the respective 95% confidence intervals, 
were used. Quantitative variable between groups were ana-
lyzed with the Mann–Whitney test, and Wilcoxon test was 
applied to verify if there were differences in the collections 
before and after each moment, confidence interval was 95%. 
Data Analysis and Statistical Software for Professionals 
(Stata), version 11.0, was the statistical package used.
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Results
The mean age in the control group was 63.9 years (SD 
±15.8), and in the intervention group it was 52.1 years 
(SD±21.5). All of the patients from both groups suffered 
from systemic hypertension. Diabetes was present in 
60.8% of the patients in the intervention group and in 
65.2% in the control group.
Table 1 shows the characterization of the samples, taking 
parameters like gender, Kt/V, hemoglobin and ferritin into 
consideration.
Table 2 shows the mean values of troponin pre- and 
post-dialysis in control and intervention groups. Interest-
ingly, between the moments of pre- and post-dialysis the 
significance value was <0.05 (p<0.05) according to the 
Wilcoxon test, demonstrating that the RIPC did not have 
the expected effect.
In Table 3 it can be observed that there were no significant 
variations in the point estimation for urea, URR and troponin 
between control and intervention groups.
Discussion
It is known that chronic kidney disease patients on hemodi-
alysis, even those without acute coronary disease, have high 
serum levels of troponin.
So far, very few management strategies have been 
proposed to reduce myocardial damage caused by hemo-
dialysis. Remote ischemic preconditioning is one of the 
propositions.7,8
Troponin is the biomarker of choice for the analysis of 
myocardial ischemia due to the fact that it is an enzyme 
specific to the cardiac muscle that plays an important role 
in the muscle contraction process; moreover, it practically 
has no relation with skeletal muscles. Most of the studies use 
troponin T (TnT) as a marker; studies using troponin I (TnI) 
are not only few but also short-term, with a small number 
of patients included.9 
A 2012 study on the predictive value of troponin in 
patients on hemodialysis revealed a strong discrepancy 
between TnT and TnI values, which can be explained by 
their molecular mechanisms, like structure, molecular weight 
and half-life.10 Besides, the kinetics of enzyme release in the 
circulation after the alterations in myocyte membrane perme-
ability can be different, and there is a divergence between the 
clearance of both enzymes Once released in the circulation, 
TnI becomes more susceptible to modifications owing to 
phosphorylation, oxidation and proteolysis.
Factors like aggressive ultrafiltration and intradialytic 
hypotension are associated with the aggravation of the 
myocardial ischemic condition during a hemodialysis ses-
sion owing to the significant alterations in the coronary 
flow. Repeated injuries induced by ischemia followed by 
Table 1 Characterization of samples according to the studied 
groups
Studied 
variables
Groups p*
Control Intervention
Gender, n (%)
Female 9.0 (40.9) 8.0 (34.8) 0.672*
Male 13.0 (59.1) 15.0 (65.2)
Kt/V 1.5 (1.1–1.5) 1.5 (1.1–1.6) 0.846**
Hemoglobin, g/dL 10.6 (10.4–11.5) 11.1 (10.8–11.6) 0.190**
Albumin, g/dL 3.8 (3.6–4.0) 4.0 (3.9–4.1) 0.010**
Ferritin, ug/L 560.0 (364.9–563.5) 375.0 (278.1–391.7) 0.076**
Notes: Confidence interval of 95% shown in brackets; *chi-square; ** Mann–
Whitney test.
Table 2 Point estimation (interval estimation) of troponin concentration according to the moments in control and intervention groups
cTn Control Intervention
Pre Post p* Pre Post p*
Troponin 1 0.010 (0.006–0.016) 0.009 (0.006–0.023) 0.631 0.007 (0.006–0.012) 0.007 (0.006–0.011) 0.152
Troponin 2 0.010 (0.006–0.014) 0.011 (0.006–0.018) 0.634 0.009 (0.006–0.017) 0.006 (0.006–0.014) 0.987
Troponin 3 0.011 (0.006–0.018) 0.013 (0.007–0.027) 0.024 0.007 (0.006–0.018) 0.006 (0.006–0.009) 0.136
Notes: Values expressed in median (confidence interval of 95%); *Wilcoxon test.
Table 3 Point estimation of concentration variation of urea, troponin and urea reduction ratio between groups
Markers Groups p**
Control Intervention
Urea* 63.50 (36.86–89.35) 75.75 (35.86–104.52) 0.672
Troponin* –0.001 (–0.0064–0.0021) 0.001 (–0.0014–0.0014) 0.441
Urea reduction ratio * –0.650 (–8.074–11.427) 4.500 (–8.090–13.901) 0.503
Notes: Values expressed in median (confidence interval of 95%); *variation between the first and last collection; **Wilcoxon test.
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 reperfusion cause alterations in motility and loss of contrac-
tility, which may lead to myocardial fibrosis and irreversible 
left ventricular systolic dysfunction.11
Burton et al showed that nearly 50% of patients on 
hemodialysis developed alterations in regional myocardial 
motility, and also that the mortality rate among these patients 
increased in the subsequent 12 months.4
No RIPC benefits, performed in three consecutive hemo-
dialysis sessions in this study, could be observed. However, 
Park et al reported its beneficial effects in 12 consecutive 
hemodialysis sessions, when a decrease in TnT levels could 
be observed.12
This study faced some limitations. First, the number of 
sessions was lower than in other published studies, and it is 
not surely known how many interventions are necessary to 
obtain such benefits. The presence of diabetes is a positive 
predictive factor for higher cardiovascular mortality. More-
over, coronary collateral circulation in diabetic patients is 
higher due to the presence of ischemia, a factor that may be 
responsible for the lower response rate in patients undergo-
ing RIPC. The studied sample included a diabetic population 
of  >50%.5, 13
In sum, in the model of three consecutive hemodialysis 
sessions, no significant reduction in ultrasensitive troponin 
I concentrations could be observed when remote ischemic 
preconditioning was applied.  
Disclosure
The authors report no conflicts of interest in this work. 
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